Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies. Blood cancer discovery Ribas, A., Dhodapkar, M. V., Campbell, K. M., Davies, F. E., Gore, S. D., Levy, R., Greenberger, L. M. 2021; 2 (6): 562-567

Abstract

Patients with hematologic malignancies are particularly vulnerable to COVID-19 infections, and upon a pooled data analysis of 24 publications, there is evidence that they have suboptimal antibody responses to COVID-19 vaccination and boosters. To provide them the needed additional protection from COVID-19, it is imperative to achieve a 100% full immunization rate in health care workers and adult caretakers, and to foster research to test higher doses and repeated rounds of COVID-19 vaccines and the use of passive immune prophylaxis and therapy.

View details for DOI 10.1158/2643-3230.BCD-21-0166

View details for PubMedID 34778796

View details for PubMedCentralID PMC8580613